Dec. 19, 2024 — Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative diseases. The compound, ... Study Supports New Blood ...
The slow uptake could stem in part from a disparity in physician attitudes to the new drugs, with some seeing them as an important new treatment option for Alzheimer's – the first with the ...
Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...